Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ: SOPH) announced a collaboration with the Mount Sinai Health System to adopt the AI-powered SOPHiA DDM™ Platform for blood cancers and solid tumors to strengthen NGS testing and genomic interpretation.

Mount Sinai will use the platform to reduce manual analysis time, improve turnaround, and scale interpretation across complex genomic datasets; Mount Sinai treats over 4,000 oncology patients annually. The announcement was made at AACR 2026.

News Market Reaction – SOPH

+0.99%

+0.99% Session close to close

In the Apr 16 session, SOPH gained 0.99%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a high-profile Mount Sinai collaboration to SOPHiA GENETICS’ expanding networ...

Analysis

This announcement adds a high-profile Mount Sinai collaboration to SOPHiA GENETICS’ expanding network of more than 990 institutions using its decentralized SOPHiA DDM™ platform. It reinforces the company’s focus on AI-driven next-generation sequencing and precision oncology. In context of prior U.S. health-system wins and recent revenue growth, investors may watch for tangible volume ramp, further large-system deals, warrant exercise activity under the F-3 (up to 75,000 shares at $5.1829), and ongoing operating losses highlighted in recent earnings.

Key Figures

Oncology patients: more than 4,000 patients annually Global institutions: more than 990 institutions Current price: $5.07 +5 more

8 metrics

Oncology patients more than 4,000 patients annually Mount Sinai oncology care volume

Global institutions more than 990 institutions Sites using SOPHiA GENETICS' decentralized platform

Current price $5.07 Pre-news price context

52-week range $2.58 – $5.70 Pre-news 52-week low and high

Warrant exercise price $5.1829 Exercise price for Second Amendment warrant shares

Warrant proceeds max $388,717.50 Maximum proceeds if all registered warrant shares exercised

Registered warrant shares 75,000 shares Ordinary shares registered on F-3 for resale

Warrant expiry Jan 23, 2036 End of warrant exercise period

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 03	Q4/FY 2025 earnings	Positive	-11.3%	Reported strong revenue growth and margins but continued losses and guidance update.
Feb 25	Conference appearance	Neutral	+1.3%	Announced leadership fireside chat at TD Cowen health care conference.
Feb 17	Earnings date notice	Neutral	+0.2%	Scheduled Q4 and full-year 2025 results release and conference call.
Feb 10	US expansion deal	Positive	-1.4%	Signed two major U.S. health systems to expand SOPHiA DDM™ use.
Jan 15	Awards announcement	Positive	+0.2%	Axalta reported multiple innovation awards and efficiency-focused products.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive operational news has sometimes seen negative price reactions, while neutral announcements often coincided with modest gains.

Recent Company History

Over recent months, SOPHiA GENETICS reported Q4 and full-year 2025 revenue of $21.7M and $77.3M, respectively, with 74.2% adjusted gross margin but an IFRS net loss of $79.0M. The company reaffirmed 2026 revenue guidance of $92M–$94M and projected adjusted EBITDA breakeven around end-2026. It also announced a major U.S. expansion via two integrated health systems and participated in investor conferences. Today’s Mount Sinai collaboration extends this pattern of network and platform adoption news.

Key Terms

next-generation sequencing, ngs, genomic variants, precision oncology, +4 more

8 terms

next-generation sequencing medical

"strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

ngs medical

"strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors"

A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.

genomic variants medical

"enable detection and interpretation of a wide range of complex genomic variants"

Changes or differences in an organism’s DNA sequence—like typos in a long instruction manual that can alter how a gene works. Investors care because these variations can determine whether a medical test, drug or therapy will work, who will be eligible, and how large the market or regulatory hurdles might be; they therefore influence clinical trial results, product demand and potential revenues.

precision oncology medical

"deeper genomic understanding to help shape the future of precision oncology"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

cloud-native technical

"delivering scalable, cloud-native solutions that empower healthcare institutions"

Cloud-native describes a way of creating and running applications that are designed specifically to operate smoothly on cloud computing platforms. Think of it as building a house with flexible, lightweight materials that can be easily moved, scaled, or adjusted as needed, rather than using rigid, traditional construction. For investors, it signifies technology that is more adaptable, efficient, and capable of quickly responding to changing market demands.

decentralized platform technical

"more than 990 global institutions using SOPHiA GENETICS' decentralized platform"

A decentralized platform is a system that runs across many independent computers instead of being controlled by one central company, using shared rules and records so no single party can change things alone — think of a neighborhood where neighbors enforce rules together rather than a single mayor. For investors, decentralization affects who controls the service, how resilient and secure it is, how decisions are made, and where regulatory or counterparty risks may lie, all of which influence value and long-term viability.

ai-powered technical

"will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research"

"AI-powered" describes technology that uses artificial intelligence to perform tasks, make decisions, or analyze information automatically. It’s similar to having a highly skilled assistant that can learn from data, recognize patterns, and improve over time, helping to make processes faster and more accurate. For investors, this means better insights and more efficient operations, potentially leading to smarter investment choices.

genomic testing medical

"advance cancer research and enhance genomic testing capabilities"

A laboratory process that reads and analyzes a person’s DNA to identify genetic variations linked to disease risk, treatment response, or drug targets; think of it as reading a biological blueprint to predict problems and guide medical choices. Investors care because results drive demand for certain diagnostics, targeted therapies, and clinical trial designs, so advances, approvals, or reimbursement changes can directly affect revenue prospects and the value of healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities.

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™ to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.

By combining Mount Sinai's clinical excellence with SOPHiA DDM™'s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.  

Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: "The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care."

John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Mount Sinai is widely regarded as one of the world's leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology."

By utilizing the SOPHiA DDM™ for Blood Cancers and SOPHiA DDM™ for Solid Tumors applications, Mount Sinai joins a growing network of more than 990 global institutions using SOPHiA GENETICS' decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS' mission to democratize data-driven medicine, delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.

The collaboration was announced from the American Association for Cancer Research® (AACR) Annual Meeting in San Diego. Learn more by connecting with SOPHiA GENETICS at AACR booth #4248 from April 17 – 22, 2026.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.  

About SOPHiA GENETICS   
SOPHiA GENETICS (NASDAQ: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Clinical use of SOPHiA DDM™ by Mount Sinai is conducted pursuant to Mount Sinai's independent validation and operation as a laboratory developed test (LDT) within its CLIA-certified, CAP-accredited laboratory. SOPHiA GENETICS does not perform diagnostic testing. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.  

View original content to download multimedia:https://www.prnewswire.com/news-releases/mount-sinai-health-system-and-sophia-genetics-announce-collaboration-to-advance-precision-cancer-care-from-aacr-2026-302741809.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPH announce about the Mount Sinai collaboration on April 16, 2026?

SOPH announced Mount Sinai will adopt the SOPHiA DDM™ Platform for cancer genomic testing and research. According to the company, this will strengthen NGS capabilities for blood cancers and solid tumors and streamline interpretation workflows.

How will SOPHiA DDM™ affect Mount Sinai's genomic testing turnaround times?

The platform is expected to reduce hands-on analysis time and improve testing turnaround times. According to the company, Mount Sinai reported reduced manual interpretation time after integrating SOPHiA DDM™ into workflows.

Does the Mount Sinai collaboration expand SOPH's global network and customer base?

Yes, the collaboration adds to SOPH's decentralized network used by over 990 global institutions. According to the company, Mount Sinai joins this network to accelerate precision medicine and data-driven oncology care.

Which SOPHiA DDM™ applications will Mount Sinai use as part of the collaboration (SOPH)?

Mount Sinai will use SOPHiA DDM™ for Blood Cancers and SOPHiA DDM™ for Solid Tumors applications. According to the company, both applications enable detection and interpretation of complex genomic variants at scale.

When and where was the SOPH and Mount Sinai collaboration announced to investors and clinicians?

The collaboration was announced at the AACR Annual Meeting in San Diego on April 16, 2026. According to the company, SOPHiA GENETICS presented the news and invited attendees to booth #4248 from April 17–22, 2026.